Tasca Therapeutics leverages a proprietary auto-palmitoylation drug-discovery platform that integrates pathway biology, structure-based design, and precision oncology to address previously intractable cancer targets. Its lead candidate, CP-383, is a first-in-class small molecule shown in preclinical studies to deliver robust anti-tumor activity across multiple models, including tumors with limited response to existing treatments. The company has initiated a multi-center, open-label Phase 1/2 dose-escalation and expansion study to assess the safety, pharmacokinetics, and preliminary efficacy of CP-383 in patients with advanced or metastatic solid tumors; later study stages will incorporate biomarker-enriched cohorts. Tasca’s pipeline strategy focuses on genetically and functionally validated cancer drivers, aiming to reshape treatment options for patients with high unmet need. Financially, the company has secured a $67 million Series A round, providing capital to advance CP-383 through early-stage clinical development and expand its oncology pipeline. Investors in this round include Regeneron Ventures, Cure Ventures, Invus Group, and 8VC.

Total raised

$52M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2024